Improved access to GLP-1RA medications

The White House announced today that the prescription medications, Wegovy and Zepbound, used for chronic weight management, will now be covered by Medicare-covered patients for a co-pay of $50 per month. Ozempic (indicated for Type 2 Diabetes) and Wegovy (indicated for chronic weight management) will now cost $350 per month when purchased through TrumpRx. Zepbound (indicated for chronic weight management) will now cost an average of $346 per month. Orforglipron, Eli Lilly's highly anticipated oral GLP-1RA medication that will likely apply for FDA approval by the end of the year, would also be priced the same (if approved). 

Improved patient access to highly effective obesity and diabetes treatment should always be applauded, but remember that medication is only one component of comprehensive obesity care and should be monitored by an experienced obesity care provider.